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Abstract:Here, we show that volume neurotransmission and the redox property of dopamine, as well as redox-regulated 
processes at glutamate receptors, can contribute significantly to our understanding of schizophrenia. Namely, volume  
neurotransmission may play a key role in the development of dysconnectivity between brain regions in schizophrenic  
patients, which can cause abnormal modulation of NMDA-dependent synaptic plasticity and produce local paroxysms  
in deafferented neural areas. During synaptic transmission, neuroredox regulations have fundamental functions, which  
involve the excellent antioxidant properties and nonsynaptic neurotransmission of dopamine. It is possible that the effect 
of redox-linked 	
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However, knowledge of redox signal processes, including the sources and molecular targets of reactive  
species, is essential for understanding the physiological and pathophysiological signal pathways in cells and the brain, as 
well as for pharmacological design of various types of new drugs.  
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INTRODUCTION 
  Converging evidence for the neurodevelopmental theory 
of schizophrenia suggests that a disturbance of brain devel-
opment, involving genetic and environmental factors, during 
the intrauterine period and the first few years after birth un-
derlies the later appearance of psychosis during adulthood 
[1]. However, the pathophysiology of schizophrenia is very 
complex and involves several cortical and subcortical sys-
tems. Brain imaging methods such as fMRI and PET have 
shown that differences linked to the neurocognitive deficits 
in schizophrenia most commonly occur in the frontal lobes, 
temporal lobes and hippocampus [2]. There have also been 
findings of differences in the structures and sizes of definite 
brain areas in schizophrenia. 
  The dopamine hypothesis of schizophrenia has been the 
major neurochemical assumption for over 40 years. This 
hypothesis is based on two fundamental observations: dopa-
mine-enhancing drugs can produce psychosis, and blockade 
of D2 dopamine receptors is the sole property common to all 
antipsychotic drugs [3]. The dopamine hypothesis of schizo-
phrenia proposes that excess activation of D2 receptors is the 
cause of the positive symptoms (delusions, hallucinations, 
and thought disorder) in schizophrenia. However, antipsy-
chotic drugs that block dopamine D2 receptors are highly 
effective in treating the psychosis, but have limited effects 
on the negative symptoms (deficits in social abilities and 
speech, affective flattening). 
  Another hypothesis concerning the cause of schizophre-
nia postulates a deficit of glutamate functioning [4, 5].   
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Usually, it focuses on the glutamate neurotransmitter and the 
abnormally low level of the NMDA glutamate receptor in 
schizophrenia based on postmortem brains of people previ-
ously diagnosed with schizophrenia. The glutamate hypothe-
sis is also supported by the fact that glutamate-blocking 
drugs such as ketamine and phencyclidine imitate the psy-
chotic symptoms of schizophrenia. 
  Schizophrenia is also characterized by deficits of sero-
tonin (5-HT) [6, 7] and norepinephrine [8]. Functional inter-
actions between the central serotonin and dopamine (DA) 
systems have been well documented [9]. Alterations in the 
brain serotonin-dopamine balance are implicated in the etiol-
ogy of schizophrenia. Numerous studies have shown that 5-
HT receptors can modulate dopaminergic functions. How-
ever, the modulating effect of serotonin on striatal dopamine 
release is controversial. For instance, serotonin could inhibit 
[10, 11] or stimulate DA release in the striatum [12, 13].   
The serotonin hypothesis is also supported by the known 
hallucinogenic effect of 5-HT receptor agonists, such as   
lysergic acid diethylamide (LSD), hallucinogenic derivatives 
of phenethylamine and tryptamine [14]. 
  The hypofunction of subsets of GABAergic interneurons 
in the prefrontal cortex and the hippocampus was also sug-
gested in schizophrenia [15]. The cholinergic system in-
cludes two families of receptors (muscarinic cholinergic and 
the nicotinic cholinergic receptors) that use acetylcholine as 
a neurotransmitter. Pharmacology, neuroimaging, and post-
mortem studies suggest alterations in the muscarinic cho-
linergic system in schizophrenia [16]. 
  Mitochondrial dysfunction has also been proposed as a 
cause of schizophrenia, including dysfunction of the oxida-
tive phosphorylation mechanisms, mitochondrial hypoplasia, 
and altered mitochondria-related gene expression [17]. There 
is also some evidence of irregular cellular metabolism and 290 Current Neuropharmacology, 2011, Vol. 9, No. 2 Bókkon and Antal 
oxidative processes in the prefrontal cortex in schizophrenia, 
involving increased glucose demand and/or cellular hypoxia. 
  In addition, convergent evidence has implicated devel-
opmental dysregulation of glutathione (GSH) synthesis in the 
pathogenesis of schizophrenia [18-20]. Lack of regulation of 
neural calcium homeostasis has also been suggested as a link 
between the dopaminergic and glutamate abnormalities [21]. 
However, there is accumulating evidence for the presence of 
oxidative stress states (dysregulated redox processes) in di-
verse psychiatric disorders, which suggests that redox path-
ways present potential treatment targets that may be applica-
ble to multiple disorders. 
  Here, we argue that the volume neurotransmission, anti-
oxidant and pro-oxidant properties of dopamine, as well as 
redox processes at various glutamate receptors, may be   
essential to understanding schizophrenia. Fig. (1) demon-
strates very complex features of several redox processes   
during activation of glutamate receptors. 
MONOAMINERGIC NEUROTRANSMISSION IS 
PREDOMINANTLY NONSYNAPTIC 
  Since Santiago Ramón y Cajal discovered gaps between
neurons [22], neurotransmission has been considered to be a 
point-to-point synaptic connection. However,  
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have fundamental regulating roles in both presynaptic and 
postsynaptic processes. 
  The vast majority of monoaminergic varicosities create 
nonsynaptic contact that permit the release of transmitters 
directly into the extrasynaptic areas. It is estimated that about 
95% of catecholamine (the most abundant catecholamines 
are dopamine, norepinephrine, and epinephrine) terminals 
are nonsynaptic and that each neuron is positioned within 
less than 30 m of a norepinephrine bouton in the brain   
[27].  
REACTIVE SPECIES AS FUNDAMENTAL CELLU-
LAR SIGNALS  
  Thus far, reactive oxygen species (ROS) - hydrogen per-
oxide (H2O2), superoxide anion (O2
 .), hydroxyl radical 
(HO
.), and singlet oxygen (
1O2) - and reactive nitrogen spe-
cies (RNS) - nitric oxide (NO
.) and peroxynitrite anion 
Fig. (1). Dopamine volume neurotransmission and some redox processes during activation of NMDA, AMPA and MGLU receptors.
DA, dopamine; NO, nitric oxide; NO Syn, nitric oxide synthetase; MGLU, metabotropic glutamate receptor; NMDA, N-methyl-d-aspartate 
ionotropic glutamate receptor; AMPA,  -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ionotropic glutamate receptor; PGH Syn, 
prostaglandin H synthetase;  ROS, reactive oxygen species; GLU, glutamate; H2O2, hydrogen peroxide; O2
-. superoxide anion;
 1O2 singlet 
oxygen; GSH, Glutathione. 
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(ONOO
 ) - have been considered as very harmful agents that 
cause damage to macromoleculesthrough nucleophilic attack 
[28]. These reactive species are generated primarily by   
the mitochondrial respiratory chain, NADPH oxidases,   
cyclooxygenases, lipoxygenases, cytochrome P450 oxidases, 
xanthine oxidase, nitric oxide synthase (NOS), etc. [29]. The 
harmful effects of reactive species are collectively termed 
oxidative stress and occur in biological systems when there 
is overproduction of ROS/RNS and/or a deficiency of   
enzymatic and non-enzymatic antioxidants [30, 31]. 
  However, emerging evidence indicates that reactive   
species are essential signaling molecules for cells. Recent 
findings have shown that diverse kinds of reactive species 
and several products derived from their reactions, such as 
oxidized lipids and proteins, are necessary for regulating 
biological functions at all levels of biological organization 
[29, 32]. Reactive species and their derivatives stimulate 
distinct signaling pathways that can interact with each other. 
It may be paradoxical that diverse ROS-mediated processes 
protect cells against ROS-induced oxidative stress and re-
store redox homeostasis. During physiological (pathophysi-
ology) processes, ROS and RNS can act as secondary mes-
sengers and control gene expression, apoptosis, cell growth, 
cell cycle, cell adhesion, chemotaxis, protein-protein interac-
tions and enzymatic functions, Ca
2+ and redox homeostasis, 
etc., in cells [29, 32-38]. 
REACTIVE SPECIES AS FUNDAMENTAL SIGNALS 
IN THE BRAIN 
  During neuronal activity, a considerable volume of oxy-
gen is used to maintain neuronal membrane potentials, which 
accordingly generate ROS and RNS. Various ROS and RNS 
as well as their derivatives act as signaling molecules in 
cerebral circulation and are required for signal processes 
such as synaptic plasticity and memory formation [39-41]. 
Reactive species control uptake of the excitatory neuro-
transmitter glutamate mainly by oxidation of protein sulfhy-
dryl groups in rat cortical astrocytes [42]. 
  The NO (nitric oxide) free radical molecule can freely 
cross cell membranes, acting as a neurotransmitter, neuro-
modulator, and messenger. Neuronal NO modulates synaptic 
activity by regulating neurotransmitter release and takes part 
in processes involved in synaptic plasticity, such as long-
term potentiation, depression and synaptogenesis [43-46]. 
NO, as a diffusible messenger, increases glutamate release in 
NMDA receptor activation processes [47]. 
  NADPH oxidases (nicotinamide adenine dinucleotide 
phosphate-oxidase) and other sources of superoxide are re-
quired for the hippocampal long-term potentiation (LTP) and 
hippocampus-dependent memory [48-51]. 
  The NMDA subtype of glutamate receptors consists of a 
complex of various subunits. Since numerous cysteine resi-
dues are located in NMDA receptor subunits, which are re-
dox-regulable, ROS and NO have important mediators of 
NMDA receptor signaling processes. During NMDA recep-
tor activation, NADPH oxidase generates ROS via signaling 
pathway involving NO, cyclic guanosine monophosphate 
(cGMP), and protein kinase G (GPKG) [52]. 
  Hydrogen peroxide (H2O2) is emerging as a ubiquitous 
messenger in various cells and the brain. Oxidative deamina-
tion of monoamines by mitochondrial MAO is accompanied 
by the reduction of molecular oxygen to H2O2. Recently, Bao 
et al., [53] demonstrated that respiring mitochondria are the 
primary source of H2O2 generation for dynamic neuronal 
signaling. 
  In brief, many experiments have provided evidence that 
reactive species act as essential signals during physiological 
(pathophysiological) processes in cells and the brain. 
MITOCHONDRIAL NETWORKS AS REDOX   
CENTERS AND METABOLIC HUBS  
  To date, usually, mitochondria are considered as simple 
cellular energy sources in most scientific literatures. How-
ever, there is accumulating evidence that mitochondria func-
tion as essential centres for cellular signaling pathways in 
cells. According to Aon et al., [54, 55] mitochondria can 
function as metabolic hubs that produce ROS signaling 
molecules with scale-free dynamics. Namely, the coordina-
tion between mitochondria within the network appears to be 
ROS mediated. Mitochondria are poised at the convergence 
of most anabolic and catabolic pathways through the tricar-
boxylic acid cycle. Thus, mitochondria can act as metabolic 
and redox hubs due to their numerous links to other path-
ways as inputs (sources) or outputs (sinks). In addition, 
growing evidence demonstrates that shapes and spatiotempo-
ral arrangements of mitochondria can be very different in 
different cell types [56]. Moreover, activity-dependent mito-
chondrial redistribution takes place in neurons [57]. 
  Mitochondria are essential determinant of the excitability 
and viability of neurons. Mitochondria take up about 25% of 
the cell volume in neurons and play fundamental roles in 
cellular redox and Ca
2+ homeostasis, ATP generation, free 
radical production, regulation of neurotransmitter release, 
cell growth, apoptosis, cell signaling, iron metabolism,   
steroidogenesis, and many other functions [40, 58]. 
  In contrast to the textbook description of mitochondria as 
small spherical organelles in cells, mitochondria in muscular, 
neuronal and connective tissue are principally filamentous 
[56, 59, 60]. Mitochondria are functionally connected, i.e., 
they produce a dynamic network within neuronal cells. Mi-
tochondria continuously fuse and divide, and their morphol-
ogy and intracellular distribution change according to the 
energy demands of cells [61, 62]. Because mitochondria are 
key players in cellular redox homeostasis and signaling and 
one of the main sources of free radicals, they play a central 
role in redox-dependent post-translational reversible oxida-
tive modifications of proteins such as tyrosine phosphatases 
and protein tyrosine kinases. 
  Mitochondria also participate in the synthesis and secre-
tion of neurotransmitters. Some essential steps in the me-
tabolism of the major excitatory neurotransmitter glutamate 
and the principal inhibitory neurotransmitter GABA 
(gamma-aminobutyric acid) take place in the mitochondrial 
tricarboxylic acid cycle [63]. 292    Current Neuropharmacology, 2011, Vol. 9, No. 2 Bókkon and Antal 
  Besides, mitochondrial monoamine oxidase (MAO) en-
zyme performs a key metabolic role in the turnover of sero-
tonin, dopamine, norepinephrine, and epinephrine in the 
brain [64-66]. Oxidative deamination of monoamines by 
mitochondrial MAOs is accompanied by the reduction of 
molecular oxygen to H2O2. Namely, reactive speciesare gen-
erated by mitochondrial monoamine oxidases during natural 
metabolism of serotonin, norepinephrine, epinephrine, and 
dopamine. Because oxidative deamination of monoamines 
by mitochondrial MAOs is a regulated process, reactive   
species generated during oxidative deaminations may also 
serve as essential signaling molecules in cells. 
  In contrast, excess (unregulated) production of dopamine 
(monoamines) can induce overproduction of H2O2 and su-
peroxides via monoamine oxidases, as well as leading to an 
excess of auto-oxidized dopamine that can cause lipid per-
oxidation and DNA and protein modifications and interact 
with the mitochondrial electron transport system. Dopamine 
can inhibit brain mitochondrial respiration that involves gen-
eration of reactive oxygen species [67]. In addition, dopa-
mine-associated inhibition of mitochondrial respiration is 
dependent on MAO and H2O2 [68].  
DOPAMINE AND SEROTONIN CAN REVERSIBLY 
REGULATE MITOCHONDRIAL MOTILITY AND 
DISTRIBUTION 
  Recently, it was demonstrated that the neurotransmitter 
dopamine and serotonin (5-HT) can reversibly regulate mito-
chondrial motility and distribution in cultured hippocampal 
neurons [69, 70]. Chen et al., found that dopamine bears a 
net inhibitory effect on mitochondrial movement. In contrast, 
5-HT performed a stimulatory effect on mitochondrial 
movement. Chen et al. suggested that dopamine and 5-HT 
can determine the distribution of mitochondria as energy 
sources in neurons. 
  However, because mitochondria can function as meta-
bolic and redox hubs, the distribution of mitochondria repre-
sents a distribution not only of energy sources but also of 
metabolic and redox processes. In other words, when dopa-
mine and 5-HT determine the distribution of mitochondria in 
neurons, they also determine cellular redox and Ca
2+  pat-
terns, ATP generation patterns, free radical patterns, spatio-
temporal patterns of various cell signals, neuronal membrane 
potentials, and many other parameters. It is very possible that 
other neurotransmitters, such as norepinephrine and acetyl-
choline, can also affect mitochondrial movement and distri-
bution. 
CATECHOLAMINES AND SEROTONIN AS ANTI-
OXIDANTS 
  Catecholamines and serotonin and their metabolic prod-
ucts can be either neurotoxic or neuroprotective. However, 
catecholamines and serotonin bear free radical scavenging 
and neuroprotective abilities [71-74]. At high doses, catecho-
lamines induce apoptosis but prevent free radical-mediated 
neurotoxicity as antioxidants without being coupled to the 
receptors [74]. The catechol structure is a fundamental com-
ponent for the antioxidative effect of catecholamines. The 
redox state of the cell is largely linked to the iron (and cop-
per) redox couple and is maintained within strict physiologi-
cal limits. Catecholamines can inhibit generation of free 
radicals by chelating various metals; i.e., they can balance 
redox potential by complex formation [75, 76]. 
  Serotonin and its precursor have great antioxidant proper-
ties in the brain [73]. Serotonin attenuates free radical-
induced neuronal death without being coupled to serotonin 
receptors in cultured mouse cortical neurons [77]. Norepi-
nephrine reduces caspase activation and ROS production in 
cholinergic neurons [78]. 
Dopamine and its five receptor subtypes play various roles in 
the central nervous system. Dopamine exerts its actions 
through two families of cell surface receptors that belong to 
the class of G protein-coupled receptors. D1-like receptors 
(D1, D5) stimulate adenylyl cyclases, while D2-like recep-
tors (D2, D3, D4) inhibit adenylyl cyclases [79]. Activation 
of D1 and D5 receptors produces antioxidant responses [80, 
81]. Antioxidant response to the D5 induction is mediated by 
inhibition of NADPH oxidase activity [80]. Besides, dopa-
mine has concentration-dependent effects on ROS produc-
tion. It acts as an antioxidant at physiologicalconcentrations, 
but as a prooxidant at higher concentrations. The neuropro-
tective outcomes of dopamine can be both receptor-mediated 
and non-receptor-mediated [82]. However, dopamine is   
a potent antioxidant, and when it reduces reactive oxygen   
species, it is converted into neurotoxic dopamine oquinones. 
Dopamine oquinone can rapidly recover to dopamine by an 
ambient antioxidant such as glutathione or ascorbate. In the 
absence of ambient antioxidants, oquinones form neurotoxic 
osemiquinones, which are free radicals [83]. 
  Because mitochondria play key roles in the synthesis and 
secretion of classical neurotransmitters and that catechola-
mines and serotonin can act as antioxidants and free radical 
scavengers, mitochondria can also control redox processes 
via the regulation of neurotransmitter metabolism and secre-
tion. 
GLUTATHIONE IN SCHIZOPHRENIA 
  The cellular thiol redox state is a fundamental mediator 
of numerous signaling, metabolic, and transcriptional proc-
esses in cells. The glutathione (GSH) and thioredoxin (TRX) 
systems are the two key and ubiquitously expressed antioxi-
dant systems that reduce thiol (-SH) groups [84]. The GSH 
and TRX systems maintain a reduced intracellular redox 
condition in cells by the reduction of protein thiol groups. 
Namely, they keep signaling components in a reduced state 
and are counterbalanced in signaling by oxidative mecha-
nisms. GSH (g-glutamyl-cysteine-glycine, a tripeptide that 
exists in reduced monomeric (GSH) and oxidized dimeric 
forms (GSSG)) is the major thiol antioxidant and redox 
buffer in cells and is abundant in the cytosol, nuclei, and 
mitochondria. 
  There is increasing evidence that the glutathione metabo-
lism is abnormal in schizophrenia and that a weakened ca-
pacity to synthesize GSH under oxidative stress is a suscep-
tibility factor for schizophrenia. Namely, patients with 
schizophrenia indicate a deficit in glutathione levels in the 
prefrontal cortex and cerebrospinal fluid, as well as the re-Schizophrenia: Redox Regulationand 	
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duction of gene expression of GSH-synthesizing enzymes 
[18, 19, 85]. However, glutathione can act as a neuromodula-
tor at the glutamate receptors and as a neurotransmitter at its 
own receptors. GSH plays a major role in modulating redox-
sensitive sites, including NMDA receptors [86]. In slices of 
rat hippocampus, reduced GSH levels weaken NMDA-
mediated responses and synaptic plasticity [20]. 
 Cabungcal  et al. [87] provide experimental evidence that 
glutathione deficit, during postnatal development, induces 
dysfunctions in GABAergic neurons in anterior cingulate 
cortex of rats. These dysfunctions of GABAergic interneuron 
can have wide-ranging effects on the neuronal circuitry of 
prefrontal cortex and its output to additional brain areas. 
REDOX REGULATION AT IONOTROPIC NMDA 
RECEPTORS 
  Glutamate activates two types of glutamate receptors: 
ionotropic (iGluRs) and metabotropic glutamate receptors 
(mGluRs) [88]. Ionotropic glutamate receptors have been 
subdivided into -amino-3-hydroxy-5- methylisoxazole-4-
propionic acid (AMPA), kainite, and N-methyl-D-aspartate 
(NMDA) receptor subclasses. 
  It is accepted that the glutamate ionotropic NMDA recep-
tor is the principal molecular structure for controlling synap-
tic plasticity and memory function. NMDAR activation starts 
several events, including calcium influx, activation of nitric 
oxide synthase, and superoxide formation [89, 90]. Earlier 
studies have suggested that mitochondria are a principal 
source of NMDA-induced superoxide production. However, 
recent experiments have indicated that NADPH oxidase can 
be the main source of superoxide production following neu-
ronal NMDAR activation [91]. It is probable that initial su-
peroxide signals produced by NADPH oxidase can stimulate 
secondary mitochondrial superoxide production. 
  Redox modulation has been recognized as an essential 
system in the regulation of the NMDA receptor [86]. Oxidiz-
ing agents decrease, but reducing agents enhance NMDA-
evoked currents. Numerous cysteine residues are located in 
NMDA receptor subunits, which are redox-regulable. 
  It is possible that redox agents can produce conforma-
tionalchanges in the NMDAR protein at cysteine residues to
promote or inhibit the development of disulfide bridges, 
which induce changes in channel properties [92]. The 
NMDA receptor can also be regulated by nitric oxide (NO)-
related species (not involving cyclic GMP) and endogenous 
glutathione [86]. 
  During excitation of a neuron by glutamate, nitric oxide 
is produced that stimulates exocytosis and release of dopa-
mine and glutamate from nearby neurons [93]. Thus, dopa-
mine can alter the strength of glutamatergic synapses and 
affect synaptic plasticity. It is possible that n	 vol-
ume transmission of dopamine (as a form of spatiotemporal 
signaling) complements classic 	 transmission and 
organizes local activity among neuron groups. 
  Smythies has presented research about the redox bio-
chemical basis of learning and neurocomputation [94-97]. 
His theory is based on redox mechanisms at the glutamate 
synapse. He emphasized that catecholamines are potent anti-
oxidants and free radical scavengers. According to Smythies 
[94], “…it is possible that catecholamines from the en pas-
sage DA bouton (and possibly norepinephrine (NE) boutons 
in NE systems) may modulate the redox status of the adja-
cent glutamatergic synapse by scavenging ROS”. However, 
Smythies was the first who emphasized that synaptic and 
nonsynaptic (volume transmission) transmission processes 
can be redox-based mechanisms. 
IONOTROPIC AMPA GLUTAMATE RECEPTORS 
AND REGULATION OF STRIATAL DOPAMINE   
RELEASE BY DIFFUSIBLE H2O2
 AMPA  ( -amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid) ionotropic glutamate receptors are expressed in every 
part of the mammalian brain and are composed of various 
combinations of glutamate receptorsubunits (GluR1–GluR4) 
[98, 99]. Glutamate receptor subclasses can coexist in the 
same cell [100]. Subunits and splice variants of AMPA   
receptors also differ by brain region. 
  Regulation of dopamine-dependent glutamate transmis-
sion is relatively known. For instance, glutamate release can 
be inhibited by D2 dopamine receptors on corticostriatal 
afferents [101]. This dopamine regulation is achieved by 
	


.
  In contrast, how synaptically released glutamate control 
dopamine release in striatum is less understandable. How-
ever, the effect of ionotropic glutamate-receptor activation 
on dopamine release should be indirect because AMPA   
receptors are not expressed on DA terminals [103, 104].   
Several experiments support that H2O2 can function as a   
signaling messenger in the brain and other tissues by various 
H2O2 regulable processes such as kinases, phosphatases,
transcription factors, ion channels, etc. [32, 105-107]. 
 Recently,  Avshalumov  et al. [108] reported that activa-
tion of ionotropic AMPAR produce diffusible H2O2, which
opens ATP-sensitive potassium (KATP) channels and thereby 
inhibits synaptic dopamine release in striatum (the major 
input station of the basal ganglia system). In other words, the 
mechanism by which H2O2 can inhibit dopamine release is 
activation of ATP-sensitive potassiumchannels. 
  The major subcellular sources of H2O2 production are 
mitochondrial respiration, monoamine oxidase (MAO), and 
NADPH oxidase. Very freshly, Bao et al. [53] demonstrated 
that fast H2O2 production is due to the mitochondrial respira-
tion during glutamatergic activation of AMPA receptors in 
the striatum. Namely, respiring mitochondria are the major 
sources of H2O2 generation for fast, dynamic neuronal sig-
naling. In contrast, MAO and NADPH oxidase do not con-
tribute to dynamic, fast (subsecond) H2O2 signaling in the 
striatum, nevertheless these act as H2O2 sources at longer 
timescales. 
REDOX-CONTROLLED PHOSPHORYLATION OF 
NMDAR SUBUNITS  
  The phosphorylation of NMDAR subunits by protein 
kinases plays a critical role in NMDAR regulation and syn-294    Current Neuropharmacology, 2011, Vol. 9, No. 2 Bókkon and Antal 
aptic plasticity [109, 110]. For instance, NMDAR currents 
can be enhanced by increasing tyrosine kinase activity [110]. 
  Numerous studies have demonstrated that reversible oxi-
dative modifications (reversible thiol modification) of pro-
tein tyrosine kinases and protein tyrosine phosphatases by 
ROS play essential roles in regulating their enzymatic activ-
ity [111-113]. Although these oxidative modifications are 
reversible, their effects on the enzymatic activity of tyrosine 
phosphatases and tyrosine kinases can be even opposite.
Thus, protein tyrosine phosphorylation-based signaling 
pathways are under the regulation of reactive oxygen   
species. 
Li et al., suggested, [114] that an impairment in NR1 subunit 
phosphorylation of NMDA receptors produces glutamatergic 
hypofunction that can contribute to behavioral deficits   
related to psychiatric disorders. However, these findings 
indicate that phosphorylation of NMDAR subunits by pro-
tein kinases is also subject to regulation by redox and free 
radicals. 
METABOTROPIC GLUTAMATE RECEPTORS 
  The metabotropic glutamate receptors (mGluRs) are G-
protein-coupled receptors with seven transmembrane do-
mains that can modulate brain excitability via presynaptic, 
postsynaptic and glial mechanisms To date, the existence of 
eight metabotropic glutamate receptors (from mGlu1 to 
mGlu8) have been identified, and these receptors have been 
clustered into three groups (I-III). mGluRs are not ion chan-
nels but are active through an indirect metabotropic process 
[115]. mGluRs modulate the activity of ligand- and voltage-
gated ion channels by means of G-protein-mediated activa-
tion of such intracellular messenger cascades as phospholi-
pase C, adenylyl cyclase and protein kinase C. 
  In contrast to the glutamate ionotropic receptors, such as 
NMDA, AMPA and kainate receptors, which are responsible 
for fast excitatory transmission, mGluRs play modulatory 
roles in glutamatergic synaptic transmission by modulating 
the ion channel activity and neurotransmitter release. mGlu 
receptors can regulate neuronal function separately from the 
ionotropic NMDA receptors (iGluRs) and protect against 
cellular injury by regulating oxidative and redox processes. 
For instance, glutamate can induce dopamine efflux by me-
tabotropic GluR1 activation. 
  However, mGluR agonists can modulate - increase or 
decrease - the release of dopamine in the striatum and nu-
cleus accumbens [116-118]. One possible explanation for 
this contradiction is that mGluR subtypes differently modu-
late the release of extracellular dopamine in different areas of 
the brain [117]. It was suggested that mGluRs can regulate 
neuronal injury and survival, likely via protein kinases and 
cysteine protease signaling pathways that affect mitochon-
drial controlled programmed cell death [119]. 
  However, since mGluRs can modulate the release of do-
pamine (dopamine can acts as an antioxidant at physiological
concentrations and modulate the redox status of the adjacent 
glutamatergic synapse), and act via protein kinases and cys-
teine protease (ROS play essential roles in regulating their 
enzymatic activity) signaling pathways that affect mitochon-
drial processes (mitochondrial networks are the main sources 
of ROS), indicating that mGluR associated signal pathways 
are also redox-linked processes. 
MODULATION OF NMDA RECEPTORS AND   
DOPAMINE TRANSPORTERS BY ZINC  
  Functional native NMDAR, which is a heteromultimer of 
NR1 and NR2 subunits [120, 121], play multifaceted roles in 
synaptic plasticity. Zinc can act via these receptors to modu-
late bidirectional plasticity. The existence of zinc in synaptic 
terminals and its extracellular release during synaptic trans-
mission [122, 123] suggest that zinc is a significant modula-
tor of synaptic plasticity. For instance, zinc can modulate 
synaptic plasticity in hippocampal CA1 region by different 
mechanisms that are dependent on zinc concentrations [124]. 
  The dopamine transporter (DAT) is a specific membrane 
protein in dopaminergic neurons. Dopamine reuptake by 
DAT regulates the extracellular dopamine concentration in 
brain areas with dopaminergic innervation. Lately, Pifl et al.
[125] demonstrated the first evidence that DAT regulation by 
Zn
2+ is intensely modulated by the membrane potential and 
chloride. In other words, the direction (inhibitory or stimula-
tory) of the Zn
2+ effect on dopamine reuptake depends on the 
membrane potential and chloride distribution of cells. 
  Intra- and extracellular redox states are closely linked to 
various ions. During synaptic transmission, release of zinc 
ions into extracellular space serves an important modulatory 
role in plasticity. The catechol structure is an essential com-
ponent for the antioxidative effect of dopamine. However, 
dopamine may also play a functional role in the regulation of 
zinc ions by chelating them, which can in turn have an indi-
rect modulatory effect on NMDAR function and a modula-
tory effect on dopamine reuptake. In fact, some studies indi-
cate that extracellular zinc chelators modulate NMDAR in 
the CA3 region [126]. 
REDOX-RELATED EPIGENETICS IN SCHIZO-
PHRENIA 
  Recent works indicate that an epigenetic mechanism is 
also an attractive hypothesis for a molecular contribution to 
schizophrenia. Accumulating evidence shows that schizo-
phrenia may arise from the abnormal epigenetic regulation of 
multiple genes. CpG islands (made up of CpG dinucleotides 
clustered together) play a critical role in controlling gene 
expression within the promoters of specific genes. Cytosine 
methylation (i.e., formation of 5-methylcytosine, catalyzed by 
a DNA cytosine-5 methyltransferase (DNMT)) is found es-
sentially at CpG dinucleotides in animals [127, 128]. In gen-
eral, the epigenetic silencing of gene expression is related to 
the hypermethylation of CpG islands. It has been suggested 
that abnormal gene expression (for instance, of the reelin, 
glutamic acid decarboxylase, and NMDA receptor genes) in 
GABAergic neurons is a consequence of promoter hyper-
methylation mediated by the overexpression of DNA methyl-
transferase in schizophrenic patients [129-131]. 
  However, production of oxygen, free radicals and glu-
tathione (GSH) influences gene expression and chromatin 
structure [132]. GSH is the key thiol antioxidant and redox 
buffer in cells and is present in high concentrations (in  Schizophrenia: Redox Regulationand 	
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millimolar concentrations) in the cytosol, nuclei, and mito-
chondria [133]. When GSH production increases, it affects 
DNA and histone methylation by limiting the availability of 
S-adenosylmethionine (a general co-substrate involved in 
methyl group transfers), which is a cofactor utilized during 
epigenetic control of gene expression by DNA and histone 
methyltransferases. Although a great number of experiments 
have provided evidence that reactive species act as funda-
mental signals during physiological (pathophysiological)
processes in cells and the brain, stressful events can produce 
redox imbalances and unregulated free radical production in 
neurons, which cause DNA injury and can influence gene 
expression by affecting DNA (and histone) methylation. In 
addition, excess free radical production perturbs the GSH 
antioxidant and redox buffer system. In brief, redox control 
also plays an essential role in epigenetic mechanisms of 
schizophrenia. 
REDOX REGULATION AND NEUROLEPTIC   
COMPOUNDS 
Neuroleptics are antipsychotic compounds used in the 
treatment of mental illnesses. Both first-generation antipsy-
chotics (also called conventional or typical antipsychotics, 
classified according to their chemical structure, (for instance, 
chlorpromazine, haloperidol, perphenazine, etc.) and second-
generation antipsychotics (also called atypical antipsychot-
ics, classified according to their pharmacological properties, 
for instance, risperidone, quetiapine, clozapine, olanzapine, 
etc.) are principally dopamine antagonists that are effective 
in treating the positive symptoms of psychosis. More recent 
research is questioning the view that second generation anti-
psychotics are superior to first generation typical anti-
psychotics [134]. However, there is the lack of effectiveness 
of typical and atypical antipsychotic drugs on cognitive  
and emotional impairments in schizophrenia [135-137].   
Recently, there is an evolving picture about schizophrenia 
moving from dopamine to glutamatergic-centered hypothesis 
[138, 139]. 
  However, because various antipsychotics exert diverse 
effects on neurotransmitter processes, and many neurotrans-
mitters (catecholamines and serotonin) have direct free radi-
cal scavenging property, and redox modulation is an essen-
tial system in the regulation of the NMDA receptors, it 
means that antipsychotics basically effects on redox-linked 
neurotransmitter communication. 
  In addition, antipsychotics have not only therapeutic 
benefits, but they also produce significant side effects such 
as weight gain, lowered life expectancy, agranulocytosis 
(lowered white blood cell count that includes neutrophils, 
basophils, and eosinophils), tarditive dyskinesia (repetitive, 
involuntary movements, such as grimacing, tongue protru-
sion, lip smacking, rapid eye blinking, etc.), diabe-
tes,http://en.wikipedia.org/wiki/Diabetes sexual dysfunction, 
etc. [140-142]. Neuroleptics can alter the blood-brain barrier 
and increase iron transport into the brain from peripheral 
stores [143, 144], which can be linked to the extrapyramidal 
motor side effects and to the pathophysiology of tardive   
dyskinesia. However, dopaminergic function is dependent   
on redox-active iron metabolism [143]. The increase of   
redox-active iron levels in the brain may cause cognitive 
impairment. 
  Side effects of antipsychotics are also linked to the 
impairment of normal mitochondrial processes (functional 
and ultrastructural mitochondrial malfunctions) [145, 146]. 
Recently, Casademont et al. [147] concluded that both 
typical and atypical antipsychotics inhibit the mitochondrial 
electron transport chain. For instance, antipsychotic valproic 
acid induces homocysteine elevation (elevation of 
homocysteine (a thiol-containing amino acid that is formed 
when methionine is converted to cysteine) in the plasma is 
correlated with complex diseases, including cardiovascular 
and neurodegenerative diseases) that influences the redox 
homeostasis and can contribute to neuronal degeneration and 
mitochondrial dysfunctions due to its excitotoxic (chronic 
dysregulation of the intracellular Ca
2+ homeostasis) proper-
ties [148, 149]. Homocysteine decreases intracellular glu-
tathione peroxidase activity and alters mitochondrial gene 
expression, structure, and function [150].  
  However, mitochondria are key determinants of the ex-
citability and viability of neurons and operate as metabolic 
and redox hubs. In brief, both useful and harmful side effects 
of antipsychotics are also linked to the redox-dependent neu-
rotransmitter and redox-dependent neurobiochemical proc-
esses. 
SUMMARY AND CONCLUSIONS: LOCAL PAROXYSM 
AND REDOX PROCESSES IN SCHIZOPHRENIA 
  Burke suggested [151] that schizophrenic visual halluci-
nations may be due to deafferentation and dysintegration   
of definite visual structures that induce an increase in   
the excitability of deafferented neurons. This deafferentation 
is associated with an increase in spontaneous activity   
and synchronization of nerve discharges. Thus, hallucination 
may be considered as a local paroxysm in some visual   
structures. 
  Stressful events can lead to redox imbalances and in-
flammatory processes in the brain. This atypical redox regu-
lation induces anomalies, including mitochondrial dysfunc-
tions. Although gene expression changes are usually attrib-
uted to mutations, epigenetic processes also play an essential 
role in controlling gene expression. Thus, stressful incidents 
produce metabolic defects that affect epigenetic enzymes and 
cause uncontrolled overproduction of reactive species that 
alter DNA methylation and histone modifications. Finally, 
stressful- driven processes can lead to the regression of syn-
apses and deafferentiation of the brain circuits during neuro-
development. This regression entails the loss of synaptic 
spines, which is under the control of the activity of NMDA 
receptors on the spines. It is possible that during neurodevel-
opment in prenatal and early life, genetic and environmental 
stress factors cause atypical formation of separated local 
(small) neuron groups. 
  These partially isolated local neuron groups may work in 
a random manner as closed-loop synchronized units with 
increased excitability and produce local paroxysms. Hu-
mans’ brain circuitry is not mature until after age twenty. 
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growth hormones, and with concomitant increases in the 
activity of the hypothalamic–pituitary–adrenal system, atypi-
cal separated local (small) neuron groups are also activated. 
These local neuron groups can remain partially isolated 
throughout life because they are separated from the perspec-
tive of information. This may explain why schizophrenia is 
such a complex and lifelong brain disorder. 
  However, most intra- and interneuronal signal processes 
are subject to redox control and modulation in a direct or 
indirect manner, as was represented in this paper. It has been 
accepted that glutamate receptors are the primary molecular 
structure controlling synaptic plasticity and memory function 
in the brain. Several biochemical steps of NMDA receptor 
activation are redox-regulated/linked processes controlled by 
reactive species (free radicals) and their derivatives. In addi-
tion, volume transmission of dopamine can capture free radi-
cals and chelating zinc (and other) ions in the synaptic cleft 
and may have an important role in retrograde signaling via
metabotropic GluR mechanisms in a G-protein-mediated 
manner. 
  Moreover, dopamine can reversibly regulate (net inhibi-
tory effect) mitochondrial motility. Thus, excess dopamine 
can produce dysfunctions of mitochondrial distribution (i.e., 
perturbation of mitochondrial fusion and fission processes)
and metabolic functions as has also been suggested for 
schizophrenia. Because neuronal activity and energy metabo-
lism are direct coupled mechanisms, and regions high in neu-
ronal activity - particularly the glutamatergic ones - have 
high levels of mitochondrial activity, excess dopamine can 
perturb neuronal activity via the expression of mitochondrial 
networks and glutamatergic NMDA receptors. 
 Additionally,  although dopamine oquinone can rapidly 
recover to dopamine, excess dopamine production - in the 
context of insufficient antioxidants - results in formation of 
neurotoxic  osemiquinone free radicals from oquinones. 
These free radicals also cause malfunctions of synaptic proc-
esses. 
  Phosphorylation of NMDAR subunits by protein kinases 
is also free radical associated. In addition, redox-mediated 
activation of NMDA receptors induces a series of further 
redox-associated free radical signaling processes, such as 
NADPH oxidase activity, neuronal nitric oxide synthase 
(nNOS) activity, mitochondrial enzyme activity, induction of 
the arachidonic acid cascade, phospholipase A, and 
prostaglandin H (PGH) synthase. Furthermore, research has 
shown that serotonin can modulate dopaminergic functions. 
  Since dopamine can exert a net inhibitory effect on mito-
chondrial movement (mitochondria are key determinants of 
the excitability and viability of neurons and act as metabolic 
hubs) and induce overproduction of H2O2 and superoxides 
via monoamine oxidase, which inhibits mitochondrial respi-
ration, this restriction of mitochondrial movement (fusion, 
fission, redistribution) and respiration can constrain the on-
going neuronal information processes and cause closed-loop 
synchronized activity in local neuron groups that can pro-
duce local paroxysms. In addition, because the dopamine 
primordially performs volume transmission (and most   
dopamine receptors are positioned at extrasynaptic sites), 
excess dopamine production in local deafferented neuron 
areas can have an especially important regulatory effect on 
the release of various neurotransmitters (and their receptors)
and on classic synaptic communication. 
  Because the majority of dopamine (monoaminergic)
varicosities create nonsynaptic contact that enables the re-
lease of transmitters directly into the extrasynaptic space, 
catecholamines and serotonin have free radical scavengers, 
and the effect of nonsynaptic  	
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